Endothelial SGK1 as a Mediator of Vascular Stiffening: Mechanisms and Experimental Insights

Study Background and Research Question

Vascular stiffening is recognized as a strong, independent predictor of cardiovascular events, with direct implications for conditions such as hypertension, diabetes, and chronic kidney disease. Epidemiological evidence links high dietary sodium intake to increased arterial stiffness, particularly in salt-sensitive populations. However, the molecular mechanisms by which sodium handling at the endothelial level translates to altered vascular biomechanics have remained incompletely defined. Prior work has implicated the endothelial sodium channel (EnNaC) in salt-induced stiffening, but the upstream regulatory pathways controlling this effect were poorly understood. The reference study by Zhang et al. (Metabolism, 2024) sought to clarify the role of endothelial serum and glucocorticoid regulated kinase 1 (SGK1) in mediating these effects, focusing on both animal models and human endothelial cell systems.

Key Innovation from the Reference Study

The principal innovation of this research lies in its demonstration that endothelial SGK1—not merely global or smooth muscle SGK1—serves as a critical regulator of both endothelial and arterial stiffness under conditions of salt excess and mineralocorticoid activation. Using both genetic ablation and pharmacological inhibition with a selective SGK1 inhibitor, the study uncovers a mechanistic link between SGK1 activity, sodium channel regulation, and actin cytoskeletal remodeling in endothelial cells. This connection advances our understanding of how salt-sensitive hypertension and vascular remodeling develop and positions SGK1 as a promising target for future cardiovascular interventions.

Methods and Experimental Design Insights

The investigators established a mouse model of salt-sensitive vascular stiffening by administering slow-release deoxycorticosterone acetate (DOCA) pellets subcutaneously, combined with a high-salt (1% NaCl, 0.2% KCl) drinking regimen. Initial experiments involved global SGK1 knockout mice, in which blood pressure, EnNaC activity, and aortic endothelial stiffness were measured and compared to wild-type controls following DOCA-salt challenge. To specifically assess endothelial contributions, selective deletion of SGK1 in endothelial cells (EC-SGK1) was achieved by cross-breeding cadherin 5-Cre mice with sgk1^flox/flox mice.

For translational relevance, primary human aortic endothelial cells were cultured and exposed to aldosterone and high sodium concentrations, with or without co-treatment using the SGK1 inhibitor EMD638683 at 10–25 μM. Cellular stiffness was assessed using biophysical readouts, and actin polymerization states were quantified as measures of cytoskeletal dynamics. This dual approach—leveraging both in vivo and in vitro models—allowed for mechanistic dissection and validation across species.

Core Findings and Why They Matter

The study’s major findings can be summarized as follows:

• Global and EC-specific SGK1 deletion attenuates vascular stiffening: Mice lacking SGK1, either globally or selectively in endothelial cells, exhibited significantly lower blood pressure, reduced EnNaC activity, and decreased aortic endothelial stiffness after DOCA-salt treatment compared to controls (reference study).
• SGK1 regulates endothelial sodium channel activity: The data support a model in which SGK1 enhances EnNaC function, facilitating increased sodium influx and subsequent cytoskeletal changes that raise cell stiffness.
• Pharmacological inhibition with SGK1 inhibitor blocks stiffening and actin polymerization: In cultured human aortic ECs, aldosterone and high sodium increased cellular stiffness and actin polymerization, but these effects were prevented by EMD638683, a selective SGK inhibitor. This implicates SGK1 in actin remodeling downstream of sodium handling.

Collectively, these findings reveal that endothelial SGK1 is a central node linking mineralocorticoid signaling, sodium channel activity, and biomechanical remodeling. This mechanistic insight clarifies why SGK1 is a promising target in strategies aiming to blunt vascular stiffening and, by extension, lower cardiovascular risk in salt-sensitive individuals.

Comparison with Existing Internal Articles

Recent literature reviews and application notes have further contextualized the role of EMD638683 in vascular biology. For example, the article "EMD638683: Advanced Insights into SGK1 Inhibition for Vascular Research" offers a technical overview of the compound’s mechanism as a selective SGK1 inhibitor, outlining protocols for its use in both hypertension and cancer research models. Meanwhile, "Endothelial SGK1 Drives Vascular Stiffening via Salt-Induced Pathways" closely aligns with the present study, highlighting how SGK1-mediated sodium handling and actin polymerization drive arterial stiffness. These resources reinforce the current findings, emphasizing both the selectivity of EMD638683 and the value of targeting SGK1 in translational models of cardiovascular disease.

Limitations and Transferability

While the study provides robust genetic and pharmacological evidence implicating endothelial SGK1 in salt-induced vascular stiffening, several limitations should be acknowledged. The in vivo experiments, though mechanistically compelling, were conducted in a mouse model with a specific DOCA-salt protocol that may not fully recapitulate the complexity of human hypertension and vascular remodeling. Similarly, the in vitro experiments utilized cultured human aortic ECs, which—though highly relevant—cannot account for the full range of in vivo microenvironmental cues and systemic factors. The transferability of these findings to other vascular beds, or to patient populations with comorbidities, warrants further investigation. Additionally, while EMD638683 is a well-validated SGK1 inhibitor, off-target effects on other kinases such as MSK1 and PRK2 have been noted in the literature, though its selectivity is high according to product information.

Protocol Parameters

• DOCA-salt model induction: Subcutaneous implantation of slow-release DOCA pellets combined with 1% NaCl, 0.2% KCl in drinking water to induce salt-sensitive hypertension in mice.
• Genetic knockout strategy: Use of sgk1^flox/flox crossed with cadherin 5-Cre mice for endothelial-specific SGK1 ablation.
• SGK1 inhibitor treatment in cell assays: Human aortic endothelial cells were treated with 10–25 μM EMD638683 in the presence of aldosterone and elevated sodium to assess effects on cell stiffness and actin polymerization.
• Assessment endpoints: Blood pressure measurement, atomic force microscopy for cell stiffness, and quantification of actin polymerization were key readouts.
• Practical suggestion: For in vitro studies, solubilize EMD638683 in DMSO (≥18.2 mg/mL), avoid long-term storage of solutions, and use freshly prepared stock at concentrations above 10 mM when possible (see product guidance).

Research Support Resources

To facilitate the study of SGK1 in vascular or cell proliferation contexts, researchers can employ EMD638683 (SGK1 inhibitor, SKU A3389). This compound, available from APExBIO, has been validated for inhibition of SGK1 in both in vitro and in vivo models, supporting workflows in hypertension, anti-tumor, and cell signaling research. For protocol optimization and additional data on selectivity, refer to the manufacturer’s recommendations and the peer-reviewed literature cited above.